Dataset Information

Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma.

ABSTRACT: Succinate dehydrogenase subunit B (SDHB) deficiency frequently occurs in cluster I pheochromocytomas and paragangliomas (PCPGs). SDHB-mutated PCPGs are characterized by alterations in the electron transport chain, metabolic reprogramming of the tricarboxylic cycle, and elevated levels of reactive oxygen species (ROS). We discovered that SDHB-deficient PCPG cells exhibit increased oxidative stress burden, which leads to elevated demands for glutathione metabolism. Mechanistically, nuclear factor erythroid 2-related factor 2 (NRF2)-guided glutathione de novo synthesis plays a key role in supporting cellular survival and the proliferation of SDHB-knockdown (SDHBKD) cells. NRF2 blockade not only disrupted ROS homeostasis in SDHB-deficient cells but also caused severe cytotoxicity by the accumulation of DNA oxidative damage. Brusatol, a potent NRF2 inhibitor, showed a promising effect in suppressing SDHBKD metastatic lesions in vivo, with prolonged overall survival in mice bearing PCPG allografts. Our findings highlight a novel therapeutic strategy of targeting the NRF2-driven glutathione metabolic pathway against SDHB-mutated PCPG.

SUBMITTER: Liu Y

PROVIDER: S-EPMC7072390 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma.

Liu Yang Y Pang Ying Y Caisova Veronika V Ding Jianyi J Yu Di D Zhou Yiqiang Y Huynh Thanh-Truc TT Ghayee Hans H Pacak Karel K Yang Chunzhang C

Cancers 20200123 2

Succinate dehydrogenase subunit B (SDHB) deficiency frequently occurs in cluster I pheochromocytomas and paragangliomas (PCPGs). SDHB-mutated PCPGs are characterized by alterations in the electron transport chain, metabolic reprogramming of the tricarboxylic cycle, and elevated levels of reactive oxygen species (ROS). We discovered that SDHB-deficient PCPG cells exhibit increased oxidative stress burden, which leads to elevated demands for glutathione metabolism. Mechanistically, n ...[more]

PMID: 31979226

Similar Datasets

Project description:Abstract Background: SDHB immunostaining can be used to functionally characterize SDH status in PCC and PGL. Assessing SDHB expression on tumors is inexpensive and can be used as an alternative to genetic testing. More importantly, assessment of SDHB expression can be of value in interpreting Variant of Unknown Significance (VUS) in SDH related genes. Objective: To investigate the effectiveness of SDHB immunostaining as an initial screening tool in identifying germline SDH mutations and the value of SDHB assessment in the clinical characterization of our patient cohort. Design: Prospective and retrospective analysis of 57 randomly selected patients with PCC and PGL from the year 1997 to 2018. Setting: In our institution on patients referred from London and South East England including Kent, Surrey and Sussex. Patients: Predominant Caucasian Population with diverse ethnicities. 57 patients - 34 patients (14M & 20F) with PGL and 25 with PCC (15M &10F). Age (mean: 41years at diagnosis with range 9-80 years). 2 patients had both PCC & PGL and multifocal PGLs were identified in few patients with SDHD and SDHB mutation. There were 65 tumors in total included in this study. Intervention: Resected tumor SDHB immunostaining with Sigma prestige antibodies (HPA002868 100UL - Anti-SDHB Rabbit monoclonal antibody) at a dilution of 1:1000. Genetic testing performed on predominant candidate genes. Main outcome measures: Concordance of SDHB loss of expression with presence of pathogenic mutation in candidate SDH genes. Secondarily, to explore SDHB immunostaining in our patient cohort with VUS in candidate genes. Results: SDHB immunostaining was negative in 22/23 tumors in patients with confirmed SDH mutation (false negative = 1 SDHB PCC where it was weak (+)). The staining was positive in 23/24 sporadic tumors, 10/11 VUS (in SDH, MAX and TMEM genes - both PCCs & PGLs), 2/2 PCCs in MEN-2, 2/2 PCCs in NF-1 and 2/3 PCCs in VHL. The negative immunostaining in 1 PGL with VUS in SDHB may imply lack of SDH enzyme activity and hence suggestive of a pathological mutation. The sensitivity is 96% and the specificity approaches 93% if the weak positive SDHB immunostaining with SDHD and VHL tumors were to be considered concordant. The concordance was 95% in the PGL group alone. Conclusions: SDHB immunostaining is a cost effective addition to PGL and PCC tumor characterization and performs with high sensitivity and specificity. SDH functional characterization has an important role in the management of patients who do not satisfy the current criteria for genetic testing (UK genetics testing directory for PCC/PGL). 18% of patients had VUS in a SDH related gene and we have found that SDHB immunostaining provided helpful information to inform follow-up and cascade screening decisions in this group.

Project description:BackgroundPheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors that are mostly benign. Metastatic disease does occur in about 10% of cases of PCC and up to 25% of PGL, and for these patients no effective therapies are available. Patients with mutations in the succinate dehydrogenase subunit B (SDHB) gene tend to have metastatic disease. We hypothesized that a down-regulation in the active succinate dehydrogenase B subunit should result in notable changes in cellular metabolic profile and could present a vulnerability point for successful pharmacological targeting.MethodsMetabolomic analysis was performed on human hPheo1 cells and shRNA SDHB knockdown hPheo1 (hPheo1 SDHB KD) cells. Additional analysis of 115 human fresh frozen samples was conducted. In vitro studies using N1,N11-diethylnorspermine (DENSPM) and N1,N12- diethylspermine (DESPM) treatments were carried out. DENSPM efficacy was assessed in human cell line derived mouse xenografts.ResultsComponents of the polyamine pathway were elevated in hPheo1 SDHB KD cells compared to wild-type cells. A similar observation was noted in SDHx PCC/PGLs tissues compared to their non-mutated counterparts. Specifically, spermidine, and spermine were significantly elevated in SDHx-mutated PCC/PGLs, with a similar trend in hPheo1 SDHB KD cells. Polyamine pathway inhibitors DENSPM and DESPM effectively inhibited growth of hPheo1 cells in vitro as well in mouse xenografts.ConclusionsThis study demonstrates overactive polyamine pathway in PCC/PGL with SDHB mutations. Treatment with polyamine pathway inhibitors significantly inhibited hPheo1 cell growth and led to growth suppression in xenograft mice treated with DENSPM. These studies strongly implicate the polyamine pathway in PCC/PGL pathophysiology and provide new foundation for exploring the role for polyamine analogue inhibitors in treating metastatic PCC/PGL. PRéCIS: Cell line metabolomics on hPheo1 cells and PCC/PGL tumor tissue indicate that the polyamine pathway is activated. Polyamine inhibitors in vitro and in vivo demonstrate that polyamine inhibitors are promising for malignant PCC/PGL treatment. However, further research is warranted.

Dataset Information

Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma.

Publications

Targeting NRF2-Governed Glutathione Synthesis for <i>SDHB</i>-Mutated Pheochromocytoma and Paraganglioma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets